LAW OFFICES

PATENT, TRADEMARK AND OTHER INTELLÉCTUAL PROPERTY MATTERS

1420 FIFTH AVENUE, SUITE 2800 SEATTLE, WASHINGTON 98101-234

> RECEIVED **CENTRAL FAX CENTER**

> > AUG 1 9 2004

DFFICIAL

TELEPHONE: 206,682,8100

FAX: 206.224.0779 INTERNET: www.cojk.com

FACSIMILE COVER SHEET

DATE: August 19, 2004

TO: U.S. Patent and Trademark Office

Group Art Unit 1600

FACSIMILE NO:

(703) 872-9306

RE:

U.S. Patent Application No. 10/743,529 Title: METHODS AND UNIT DOSE

FORMULATIONS FOR THE INHALATION ADMINISTRATION OF AMINOGLYCOSIDE

ANTIBIOTICS

OUR REFERENCE: CHIR-1-22149

FROM:

Dennis K. Shelton Reg. No. 26,997

(Facsimile No. 206.224.0779)

MESSAGE: Transmitted herewith are the following documents:

1. Amendment Transmittal Letter (2 pages).

2. Amendment After Allowance Under 37 C.F.R. § 1.312 (5 pages).

Please file the above documents.

We have 8 pages to send, including this sheet. If any pages need to be retransmitted, please call 206.682.8100, Ext. 1200, within 15 minutes.

The information contained in this facsimile message is privileged and confidential information intended only for the use of the recipient named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address by

OFFICIAL MAIL STOP ISSUE FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

R.J. Speirs et al.

Attorney Docket No.: 17968.008 (CHIR122149)

Application No.: 10/743,529

Group Art Unit: 1626

Filed:

December 22, 2003

Examiner: E.O. Sackey

Title:

METHODS AND UNIT DOSE FORMULATIONS FOR THE INHALATION

ADMINISTRATION OF AMINOGLYCOSIDE ANTIBIOTICS

AMENDMENT TRANSMITTAL LETTER

Seattle, Washington 98101

August 19, 2004

TO THE COMMISSIONER FOR PATENTS:

A. Amendment Transmittal

Transmitted herewith is an Amendment After Allowance Under 37 C.F.R. § 1.312 in the above-identified application.

 \mathbf{x} No additional claim fee is required, as shown below.

COMPUTATION OF FEE FOR CLAIMS AS AMENDED

	Claims Remaining		Highest Number						•••
	After		Previously Paid For		Preser			Additional	
	Amendment				Extra	Rate		Fee	
Total Claims	14	_	17	=	0	х	18	-	0
Independent Claims	2	-	3	=	0	x	86	=	0
	TOTAL			8					\$0

B. Additional Fee Charges or Credit for Overpayment

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request

> LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS' 1420 Fifth Avenue Suite 2800 Scattle, Washington 98101 206.682.8100

for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application.

Respectfully submitted,

CHRISTENSEN O'CONNOR JOHNSON KINDNESS**LC

Demnis K. Shel

Registration No. 26,997 Direct Dial No. 206.695,1718

I hereby certify that this correspondence is being transmitted via facsimile to the U.S. Patent and Trademark Office, Group Art Unit 1600, at facsimile number (703) 872-9306, on August 19, 2004.

Date;

8/19/04

Carole Julyan

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS***
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

OFFICIAL MAIL STOP ISSUE FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

R.J. Speirs et al.

Attorney Docket No.: 17968.008 (CHIR122149)

Application No.: 10/743,529

Group Art Unit: 1626

Filed:

December 22, 2003

Examiner: E.O. Sackey

Title:

METHODS AND UNIT DOSE FORMULATIONS FOR THE INHALATION

ADMINISTRATION OF AMINOGLYCOSIDE ANTIBIOTICS

AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312

RECEIVED CENTRAL FAX CENTER

Seattle, Washington 98101

AUG 1 9 2004

August 19, 2004

TO THE COMMISSIONER FOR PATENTS:

INTRODUCTORY COMMENTS

Prior to issuance, please amend the above-captioned application as follows: